Media headlines about Nymox Pharmaceutical (NASDAQ:NYMX) have been trending somewhat positive on Thursday, according to Alpha One Sentiment. Alpha One, a subsidiary of Accern, ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Nymox Pharmaceutical earned a media sentiment score of 0.16 on Alpha One’s scale. Alpha One also assigned headlines about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.
Shares of Nymox Pharmaceutical (NASDAQ:NYMX) traded up 2.42% during trading on Thursday, reaching $4.65. 122,978 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $3.73 and its 200-day moving average price is $3.30. Nymox Pharmaceutical has a 52-week low of $1.62 and a 52-week high of $5.79. The stock’s market cap is $229.02 million.
COPYRIGHT VIOLATION NOTICE: This story was first published by WKRB News and is owned by of WKRB News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at http://www.wkrb13.com/markets/2065742/nymox-pharmaceutical-nymx-earning-somewhat-favorable-media-coverage-study-finds.html.
In related news, Director James George Robinson bought 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 8th. The shares were acquired at an average cost of $3.59 per share, with a total value of $179,500.00. Following the completion of the purchase, the director now directly owns 2,906,078 shares in the company, valued at $10,432,820.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 54.00% of the stock is owned by corporate insiders.
About Nymox Pharmaceutical
Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2065742/nymox-pharmaceutical-nymx-earning-somewhat-favorable-media-coverage-study-finds.html
Receive News & Ratings for Nymox Pharmaceutical Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Co. and related companies with MarketBeat.com's FREE daily email newsletter.